RIGHT Fund (CEO Younbeen Kim / Research Investment for Global Health Technology Fund) has announced its selection of 2021 research grant award recipients for an additional funding of 13.6 billion KRW.
The RIGHT Fund is a global health research funding foundation established in 2018 through the public-private partnership between the Ministry of Health and Welfare of South Korea, the Bill & Melinda Gates Foundation (BMGF), and Korean life science companies to address the medical and technological needs towards alleviating the burden of infectious diseases especially in developing countries. With the recent expansion of its funding from the Government or Korea and industry partners, the RIGHT Fund will contribute further to global public health.
The RIGHT Fund newly selected three Product Development Award and seven Technical Accelerator Award projects, and the awardees are Bore DA Biotech, EuBiologics, Fine Healthcare, GenBody, Institut Pasteur Korea, InThera, SD Biosensor, Sugentech, Texas Tech University Health Sciences Center, and Yonsei University. The research topics include ▲2nd Generation Tuberculosis LAM Assay ▲Data Platform to Improvement Diagnosis of Infectious Diseases ▲In vitro Diagnostics Test for Severe Fever and thrombocytopenia Syndrome ▲Non-replicating Protein Nanoparticles-based Rotavirus Vaccine ▲Rapid Diagnostic Test for Chikungunya Antigen ▲Safety assessment of TTCA antitubercular agents ▲Schistosomiasis vaccine ▲SurearlySmart Pro COVID-19, and ▲Typhoid Conjugate Vaccine.
Through its new investments, the RIGHT Fund is taking further leadership in supporting innovative and Korean technology driven R&D for infectious diseases endemic and emerging in developing countries.
Since its establishment in July 2018, the RIGHT Fund has selected and supported a total of 32 research projects with 41.5 billion KRW accumulated.
The CEO of the RIGHT Fund, Younbeen Kim noted, “Through the current COVID19 pandemic, our society has come to experience that infectious diseases are not only pertained to specific regions or countries but also can impact humanity’s life itself, economies, and sociocultural circumstances.” Kim added, “the RIGHT Fund will continue all its efforts to discover and support health technology advancements to correspond to the current pandemic and to prepare for future pandemics by leveraging Korea’s innovative technology.”
The RIGHT Fund is planning two additional Request for Proposals in the 2nd half of 2021. More information will be announced on the RIGHT Fund webpage.